Payment overview · 2025
General Payments
$1,319.23
66 reported records · 20 companies
Healthcare provider profile · identity verified
Steven J Rivers, MD
Allopathic & Osteopathic Physicians|Family Medicine · THE VILLAGES, FL · NPI 1477589950
Verified facts
What the public records show
CMS Open Payments records show Steven J Rivers, MD received $1,319.23 in general payments during 2025 across 66 reported records.
Amgen Inc. accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Eliquis by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $177.60 | 13.5% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.96 | 11.7% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $126.60 | 9.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $113.65 | 8.6% | 5 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $96.12 | 7.3% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $84.81 | 6.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $66.55 | 5.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.64 | 5.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $59.00 | 4.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.95 | 3.7% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $48.58 | 3.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.81 | 3.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $42.63 | 3.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $36.99 | 2.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.65 | 2.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $29.85 | 2.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.83 | 1.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $22.83 | 1.7% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.62 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.56 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,319.23 | 66 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $126.60 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $125.66 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $96.37 | 7 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $96.37 | 7 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $96.12 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $81.23 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $74.65 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $66.55 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $59.00 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $44.69 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $42.92 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $42.63 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.89 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $36.99 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $29.85 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $28.30 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $28.30 | 2 | 2025 |
Source payment records
|
|||||
| ECC Solutions Normalized: ecc solutions |
Device | Philips North America LLC | $27.17 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $26.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.83 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $22.83 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.95 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.65 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 69 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 228 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 49 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
101 | 30 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
49 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
228 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
139 | 35 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 671 | 188 |
| Atorvastatin Calcium | Atorvastatin Calcium | 660 | 196 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 600 | 179 |
| Amlodipine Besylate | Amlodipine Besylate | 552 | 169 |
| Pantoprazole Sodium | Pantoprazole Sodium | 369 | 113 |
| Simvastatin | Simvastatin | 363 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 340 | 99 |
| Omeprazole | Omeprazole | 315 | 100 |
| Lisinopril | Lisinopril | 288 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 287 | 87 |
| Ozempic | Semaglutide | 228 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 215 | 68 |
| Losartan Potassium | Losartan Potassium | 206 | 59 |
| Potassium Chloride | Potassium Chloride | 196 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 193 | 64 |
| Valsartan | Valsartan | 184 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 180 | 56 |
| Metformin Hcl | Metformin Hcl | 178 | 54 |
| Trazodone Hcl | Trazodone Hcl | 166 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 156 | 54 |
| Furosemide | Furosemide | 155 | 60 |
| Metformin Hcl Er | Metformin Hcl | 155 | 34 |
| Ezetimibe | Ezetimibe | 152 | 50 |
| Atenolol | Atenolol | 146 | 43 |
| Glimepiride | Glimepiride | 144 | 41 |
| Eliquis | Apixaban | 139 | 35 |
| Gabapentin | Gabapentin | 139 | 43 |
| Meloxicam | Meloxicam | 131 | 64 |
| Allopurinol | Allopurinol | 129 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 117 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 36 |
| Terazosin Hcl | Terazosin Hcl | 113 | 34 |
| Alprazolam | Alprazolam | 110 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 109 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 53 |
| Synthroid | Levothyroxine Sodium | 101 | 30 |
| Prednisone | Prednisone | 96 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 96 | 26 |
| Buspirone Hcl | Buspirone Hcl | 93 | 34 |
| Celecoxib | Celecoxib | 88 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 20 |
| Montelukast Sodium | Montelukast Sodium | 81 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 79 | 25 |
| Finasteride | Finasteride | 76 | 25 |
| Bupropion Xl | Bupropion Hcl | 75 | 24 |
| Donepezil Hcl | Donepezil Hcl | 75 | 22 |
| Methylprednisolone | Methylprednisolone | 73 | 67 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 30 |
| Ibandronate Sodium | Ibandronate Sodium | 70 | 22 |
| Jardiance | Empagliflozin | 69 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 69 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 42 |
| Januvia | Sitagliptin Phosphate | 66 | 13 |
| Pregabalin | Pregabalin | 63 | 26 |
| Carvedilol | Carvedilol | 61 | 19 |
| Memantine Hcl | Memantine Hcl | 59 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 20 |
| Irbesartan | Irbesartan | 58 | 18 |
| Sertraline Hcl | Sertraline Hcl | 58 | 19 |
| Spironolactone | Spironolactone | 58 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 57 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 17 |
| Vascepa | Icosapent Ethyl | 54 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 13 |
| Alendronate Sodium | Alendronate Sodium | 49 | 17 |
| Estradiol | Estradiol | 49 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 49 | 36 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Tramadol Hcl | Tramadol Hcl | 46 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 45 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 44 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 12 |
| Enalapril Maleate | Enalapril Maleate | 43 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 38 |
| Bumetanide | Bumetanide | 42 | 18 |
| Ramipril | Ramipril | 41 | 12 |
| Lorazepam | Lorazepam | 40 | 14 |
| Azithromycin | Azithromycin | 39 | 38 |
| Lovastatin | Lovastatin | 39 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 25 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 36 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Repatha Sureclick | Evolocumab | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Famotidine | Famotidine | 31 | 16 |
| Xarelto | Rivaroxaban | 31 | 11 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 22 |
| Raloxifene Hcl | Raloxifene Hcl | 29 | 11 |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 12 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Telmisartan | Telmisartan | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 25 |
| Diazepam | Diazepam | 25 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | 11 |
| Amoxicillin | Amoxicillin | 24 | 15 |
| Cefdinir | Cefdinir | 23 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Baclofen | Baclofen | 18 | 13 |
| Febuxostat | Febuxostat | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | 14 |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Alprazolam Er | Alprazolam | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Meclizine Hcl | Meclizine Hcl | 16 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Arcalyst | Rilonacept | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,319.23 · 66 records | Amgen Inc. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, COMIRNATY, CREON, Cologuard Collection Kit, ECC Solutions, EDARBI, ENTRESTO, EVENITY, Extended Holter, FARXIGA, GEMTESA, General - Pain Management, HORIZANT, JARDIANCE, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, KRYSTEXXA, LEQVIO, LINZESS, MOUNJARO, Ozempic, PREVNAR 20, PROLIA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VERQUVO, VIBERZI, VOQUEZNA, VRAYLAR, XIFAXAN, YUPELRI | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error